E Fund Management Co. Ltd. Takes Position in Dianthus Therapeutics, Inc. $DNTH

E Fund Management Co. Ltd. acquired a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the 2nd quarter, Holdings Channel reports. The fund acquired 5,094 shares of the company’s stock, valued at approximately $497,000.

Several other institutional investors also recently modified their holdings of the stock. Eagle Health Investments LP purchased a new stake in Dianthus Therapeutics in the second quarter valued at approximately $12,803,000. BlackRock Inc. bought a new stake in Dianthus Therapeutics during the second quarter valued at approximately $401,990,000. Deutsche Bank AG purchased a new position in Dianthus Therapeutics in the 2nd quarter worth approximately $6,800,000. TimesSquare Capital Management LLC purchased a new position in Dianthus Therapeutics in the 2nd quarter worth approximately $16,216,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Dianthus Therapeutics in the 2nd quarter worth $543,000. 47.53% of the stock is currently owned by institutional investors.

Insider Activity at Dianthus Therapeutics

In related news, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the transaction, the executive vice president owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the transaction, the executive vice president owned 4,000 shares in the company, valued at approximately $362,480. The trade was a 86.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 287,084 shares of company stock worth $29,615,923 in the last 90 days. Corporate insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Price Performance

Shares of DNTH opened at $109.51 on Friday. Dianthus Therapeutics, Inc. has a 1 year low of $22.76 and a 1 year high of $117.88. The stock has a 50 day simple moving average of $100.17 and a two-hundred day simple moving average of $84.80. The firm has a market cap of $5.99 billion, a P/E ratio of -26.39 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The business had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. On average, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

DNTH has been the topic of several research reports. Truist Financial raised their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. HC Wainwright upped their target price on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $124.27.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.